investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Identification and annotation of 3' UTR ends using RNA-seq data
Inanc Birol
1 Collaborator(s)
Funding source
National Cancer Institute (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Aly Karsan
BC Cancer Agency
Vancouver, Canada
Inanc Birol
BC Cancer Agency
Vancouver, Canada
Related projects
James Woodgett
Functional roles of glycogen synthase kinase-3 in cellular regulation and cancer
All cancers but non-melanoma skin cancer
Daniel Durocher
CRC Tier 1 - DNA damage
All cancers but non-melanoma skin cancer
Michael Tyers
CRC Tier 1 - Biological networks in human health and disease
All cancers but non-melanoma skin cancer
Chantal Guillemette
Pharmacogenomics program identifies genomic changes that affect adverse effects and treatment efficacy (CANADA RESEARCH CHAIRHOLDER - Tier 1)
All cancers but non-melanoma skin cancer
Carl Hansen
A high-throughput single-cell technology for the function-based discovery of monoclonal antibody antagonists of G-protein coupled receptors in cancer
All cancers but non-melanoma skin cancer
Benjamin Neel
CRC Tier 1 - Treatments for RASopathies and cancer
All cancers but non-melanoma skin cancer
Georges Mer
Post-translational Modifications in DNA Damage Response: a Structural Perspective
All cancers but non-melanoma skin cancer
Mary Mcbride
Phase-Specific and Lifetime Medical Costs of Care for Childhood Cancer in British Columbia and Ontario
All cancers but non-melanoma skin cancer
Pediatric oncology or childhood cancer
James D Marks
Antibody Research Technology Center
All cancers but non-melanoma skin cancer